Evidence map›Paper›PMID 39015606›Full record

ArticleMedical cannabis and cannabinoids

Relief in Gastrointestinal Symptoms with Medical Marijuana Over 1 Year.

Matthew P Wallingford, Erin L Kelly, Allison Herens, Daniel Hanna, Emily Hajjar, Brooke Worster

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical cannabis and cannabinoids. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matthew P WallingfordSidney Kimmel Medical School, Thomas Jefferson University, Philadelphia, PA, USA.
Erin L KellyDepartment of Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
Allison HerensDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
Daniel HannaPhiladelphia College of Pharmacy, Saint Joseph's University, Philadelphia, PA, USA.
Emily HajjarJefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA, USA.
Brooke WorsterDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Subjective improvement in gastrointestinal (GI) symptoms was assessed among patients using medical marijuana (MMJ). Methods: Participants completed surveys at 0 days, 30 days, 6 months, and 12 months with questions about the severity of their GI symptoms on a scale from 1 (mild) to 3 (severe). Results: In each survey, participants reported a significant decrease in GI symptom severity when using MMJ versus when not using MMJ ( Conclusion: In patients with chronic GI symptoms, MMJ may provide persistent symptom severity improvement. Limited product availability and mild to moderate side effects are factors to consider before trialing MMJ.

Indexed as

Adverse effectsCannabisGastrointestinal symptomsIntegrative medicineMedical cannabis

Identifiers

PMID39015606
PMCPMC11250604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.